Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 62, Issue 7, 732-738
Copyright © 2005 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, C.
Right arrow Articles by Evans, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, C.
Right arrow Articles by Evans, M.

Reports

Results of an antimicrobial control program at a university hospital

Craig Martin, Ighovwerha Ofotokun, Robert Rapp, Kerry Empey, John Armitstead, Claire Pomeroy, Ardis Hoven and Martin Evans

CRAIG MARTIN, PHARM.D., is Infectious Diseases Clinical Pharmacy Specialist and Assistant Professor, University of Kentucky Chandler Medical Center (UKCMC), Lexington. IGHOVWERHA OFOTOKUN, M.D., is Assistant Professor of Medicine, Infectious Diseases, Emory University School of Medicine, Atlanta, GA. ROBERT RAPP, PHARM.D., FCCP, is Professor of Pharmacy and Surgery, UKCMC. KERRY EMPEY, PHARM.D., is a Ph.D. degree candidate, University of Kentucky, Lexington. JOHN ARMITSTEAD, M.S., FASHP, is Director of Pharmacy Services and Assistant Dean for Medical Center Pharmacy Services, UKCMC. CLAIRE POMEROY, M.D., is Professor of Infectious Diseases and Executive Associate Dean of Medicine, University of California—Davis School of Medicine, Davis. ARDIS HOVEN, M.D., is Professor of Medicine, Infectious Diseases, UKCMC. MARTIN EVANS, M.D., is Professor of Medicine, Infectious Diseases, UKCMC, and Lexington Veterans Affairs Medical Center, Lexington.

Address correspondence to Dr. Martin at the University of Kentucky Chandler Medical Center, C-117, Lexington, KY 40536 (cmart2{at}email.uky.edu).


Purpose. The results of the first five years of an ongoing antimicrobial control program are reported.

Methods. In 1998, a multidisciplinary antimicrobial subcommittee of the pharmacy and therapeutics committee of a university hospital was formed and charged with making formulary interventions in an effort to reduce rising antimicrobial resistance rates and drug expenditures. In 1999, a number of measures were implemented for controlling antimicrobial use. Selected antimicrobials with the potential for inappropriate use or whose inappropriate use had been documented were placed in the control of physicians in the infectious diseases (ID) division. Prior approval by an ID physician was required before the pharmacy could dispense these agents. Other key interventions included removal of ceftazidime and cefotaxime from the formulary, restriction of vancomycin and carbapenem use, and replacement of ciprofloxacin with levofloxacin as the sole fluoroquinolone on the formulary. Data regarding antimicrobial use and expenditures between 1998 and 2002 were compared and analyzed.

Results. Antimicrobial use was reduced by 80% for third-generation cephalosporins and 15% for vancomycin following the implementation of the new antimicrobial policies. Antimicrobial-resistance patterns for many important gram-negative pathogens, including Pseudomonas aeruginosa, demonstrated a reversal of previous increases. In addition, the rate of methicillin-resistant Staphylococcus aureus decreased by an average of 3% each year from 1999 to 2002. Pharmacy expenditures for all antimicrobials, including antiviral, antifungal, and antibacterial agents, decreased 24.7%, with a cumulative cost saving of $1,401,126, without inflation assumptions.

Conclusion. The implementation of an antimicrobial control program decreased the use of selected antimicrobial agents and resulted in substantial reduction of expenditures for antimicrobials.

Index terms: Antibiotics; Antifungals; Anti-infective agents; Antivirals; Carbapenems; Cefotaxime; Ceftazidime; Cephalosporins; Ciprofloxacin; Costs; Drug use; Economics; Formularies; Hospitals; Levofloxacin; Pharmacy and therapeutics committee; Prescribing; Protocols; Pseudomonas aeruginosa; Quinolones; Rational therapy; Resistance; Staphylococcus aureus; Vancomycin

 



This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
D. S. Burgess and R. P. Rapp
Bugs versus drugs: Addressing the pharmacist's challenge
Am. J. Health Syst. Pharm., May 1, 2008; 65(9_Supplement_2): S4 - S15.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
E. Lautenbach and R. E. Polk
Resistant gram-negative bacilli: A neglected healthcare crisis?
Am. J. Health Syst. Pharm., December 1, 2007; 64(23_Supplement_14): S3 - S21.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
V. H. Tam, S. Adams, M. T. Larocco, L. N. Gerard, L. O. Gentry, and K. W. Garey
An integrated pharmacoeconomic approach to antimicrobial formulary decision-making
Am. J. Health Syst. Pharm., April 15, 2006; 63(8): 735 - 739.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society of Health-System Pharmacists.